329 related articles for article (PubMed ID: 11058616)
1. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
Bayoumi AM; Brown AD; Garber AM
J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
[TBL] [Abstract][Full Text] [Related]
2. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
Bennett CL; Matchar D; McCrory D; McLeod DG; Crawford ED; Hillner BE
Cancer; 1996 May; 77(9):1854-61. PubMed ID: 8646685
[TBL] [Abstract][Full Text] [Related]
3. Combined androgen blockade.
Crawford ED
Eur Urol; 1996; 29 Suppl 2():54-61. PubMed ID: 8717465
[TBL] [Abstract][Full Text] [Related]
4. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
5. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
[TBL] [Abstract][Full Text] [Related]
6. Hormonal therapy for locally advanced prostate cancer.
Einstein AB
NCI Monogr; 1988; (7):171-4. PubMed ID: 3050536
[TBL] [Abstract][Full Text] [Related]
7. Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice?
Denis L
Prostate; 1995 Nov; 27(5):233-40. PubMed ID: 7479390
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Adding Androgen Deprivation Therapy to Radiation Therapy for Men with Advanced Prostate Cancer from a U.S. Payer's Perspective.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Manag Care Spec Pharm; 2019 Feb; 25(2):225-234. PubMed ID: 30698095
[TBL] [Abstract][Full Text] [Related]
9. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
11. Combined androgen blockade.
Crawford ED
Urology; 1989 Oct; 34(4 Suppl):22-6; discussion 46-56. PubMed ID: 2508291
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy.
Labrie F; Belanger A; Simard J; Labrie C; Dupont A
Cancer; 1993 Feb; 71(3 Suppl):1059-67. PubMed ID: 8428328
[TBL] [Abstract][Full Text] [Related]
13. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen.
Akakura K; Bruchovsky N; Goldenberg SL; Rennie PS; Buckley AR; Sullivan LD
Cancer; 1993 May; 71(9):2782-90. PubMed ID: 7682149
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience.
Labrie F; Dupont A; Bélanger A; Cusan L; Giguère M; Lacourcière Y; Luthy I; Bégin D; Labrie C; Simard J
Cancer Metastasis Rev; 1987; 6(4):615-36. PubMed ID: 3327635
[TBL] [Abstract][Full Text] [Related]
15. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate.
Huben RP; Murphy GP
Cancer; 1988 Nov; 62(9):1881-7. PubMed ID: 3139279
[TBL] [Abstract][Full Text] [Related]
16. Relapse on endocrine treatment in patients with stage D2 prostate cancer. Does second-line hormonal therapy affect survival?
Matzkin H; Rangel MC; Soloway MS
Urology; 1993 Feb; 41(2):144-8. PubMed ID: 8497986
[TBL] [Abstract][Full Text] [Related]
17. Analogues of LHRH versus orchidectomy: comparison of economic costs for castration in advanced prostate cancer.
Rutqvist LE; Wilking N
Br J Cancer; 1992 Jun; 65(6):927-9. PubMed ID: 1616866
[TBL] [Abstract][Full Text] [Related]
18. Advances and trends in hormonal therapy for advanced prostate cancer.
Debruyne FM; Dijkman GA
Eur Urol; 1995; 28(3):177-88. PubMed ID: 8536770
[TBL] [Abstract][Full Text] [Related]
19. The cost and availability of therapeutic options in advanced prostatic carcinoma in Turkey.
Ilker NY; Dillioğlugil O; Akdaş A
Int Urol Nephrol; 1992; 24(2):155-7. PubMed ID: 1624259
[TBL] [Abstract][Full Text] [Related]
20. Concept and viability of androgen annihilation for advanced prostate cancer.
Mohler JL
Cancer; 2014 Sep; 120(17):2628-37. PubMed ID: 24771515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
